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Background: Pneumonitis is a rare complication of bacillus Calmette-Guerin (BCG) immunotherapy seen in patients
with urothelial cancer following the repeated administration of BCG. However, no case of BCG-induced pleurisy has
been reported.
Case presentation: We here report the first case of pneumonitis with lymphocytic pleurisy following bacillus
Calmette-Guerin (BCG) immunotherapy. Although marked T helper cell alveolitis was found by bronchoalveolar
lavage and transbronchial biopsies, no acid-fast bacillus could be identified in recovered BALF or pleural effusion.
The lymphocyte stimulation test of BCG was strongly positive. However, levels of serum and bronchoalveolar lavage
fluid KL-6, a useful marker for hypersensitivity pneumonitis (HP), were within normal ranges.
Conclusion: We speculate that the pathogenesis of our case may be a hypersensitive reaction to the proteic
component of BCG entering the lung and pleural space, which is different from the etiology of the common type
of HP.
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The intravesical or intrapelvic administration of bacil-
lus Calmette-Guerin (BCG) has been proven effective
against urothelial cancer. Compared to commonly in-
duced granulomatous inflammatory changes in the bladder,
pneumonitis is a rare complication of this immunotherapy
that is seen in less than 0.7% patients following the repeated
administration of BCG [1]. Because mycobacteria are not
detected in these patients, a hypersensitivity reaction rather
than a disseminated BCG infection is suspected in the
pathogenesis of this disorder [2]. Epithelioid noncaseating
granulomas of the lung have been identified in several cases
[3]. The frequency of complications associated with BCG
immunotherapy was shown to be significantly higher in pa-
tients with prior tuberculosis than in patients without a his-
tory of tubercular illness, which provides additional support
for this hypothesis [4].* Correspondence: shinoharat@kochi2.hosp.go.jp
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reproduction in any medium, provided the orKL-6 is a mucin-like high-molecular-weight glycopro-
tein expressed on type 2 alveolar pneumocytes and
bronchiolar epithelial cells, and was shown to be a useful
serum or bronchoalveolar lavage fluid (BALF) marker
for interstitial lung diseases including idiopathic intersti-
tial pneumonia, pneumonitis related to collagen disease,
and hypersensitivity pneumonitis (HP) caused by the re-
peated inhalation of organic antigens [5,6].
Iatrogenic pleurisy is a rare disease that is mainly induced
by the systemic administration of certain agents and is
characterized by eosinophilic pleural effusion. However,
drug-induced lymphocytic non-eosinophilic pleurisies are
rare [7]. In addition, to the best of our knowledge, there
have been no reports of HP with pleural effusion.
We here report a case of interstitial pneumonia with
lymphocytic pleurisy in the absence of elevated serum/
BALF KL-6 following intrapelvic BCG immunotherapy.Case presentation
An 86-year-old female with a history of left renal cell
carcinoma was diagnosed with right ureter cancer, and
intrapelvic BCG therapy using a single-J stent wasal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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at 81 mg once a week. Prophylactic treatment of the dis-
seminated BCG infection with a combination of isonia-
zid and rifampicin was started at the same time. The
patient exhibited a continuous fever followed by dyspnea
6 days after the third BCG treatment.
A physical examination indicated fine inspiratory
crackles in both lungs with no heart murmur. Labora-
tory data were as follows: white blood cell count, 6590/
μl (neutrophils, 80.7%; lymphocytes, 11.8%; eosinophils,
2.1%; monocytes, 4.6%; basophils, 0.8%); hemoglobin,
13.2 g/dl; platelet count, 24.7 x 104/μl; C-reactive pro-
tein, 6.07 mg/dl; serum KL-6, 171 U/ml. Severe hypox-
emia (SpO2 86%) was noted. Chest X-ray revealed
bilateral diffuse reticulonodular infiltrates and was sug-
gestive of pleural effusion. High-resolution computed
tomography (HRCT) showed ground-glass opacity, inter-
lobular septal thickening, diffuse micronodular shadows,
and bilateral pleural effusion (Figure 1a,b).
Bronchoalveolar lavage (BAL) (recovery rate; 84/150) re-
vealed high total cellularity (70 × 104 cells/ml), consisting
of 84% lymphocytes, 11% neutrophils, and 5% eosinophils.
Immunophenotyping showed that lymphocytes were 67%
CD4+ cells and 12% CD8+ cells, with a CD4+/CD8+ ratio
of 5.5. Direct microscopy, culture, and polymerase chain
reaction of the BALF remained negative for pathogens in-
cluding mycobacteria. KL-6 in the BALF was 217 U/ml
(cutoff level was 340 U/ml [6]). The concentration of
interleukin (IL)-8 in the BALF was 76.7 pg/ml (< 15 pg/ml
[8]). IL-1β, IL-10, IL-12, interferon gamma (IFN-γ), tumor
necrosis factor alpha (TNF-α), and monocyte chemotac-
tic protein-1 (MCP-1) were under the detection limits
(< 10, < 2, < 7.8, < 1.56, < 0.55 and < 62.5 pg/ml, respect-
ively). Transbronchial biopsies of the right lung (rS3 and
rS8) revealed alveolar septal thickening and lymphocyteFigure 1 HRCT of the a) upper and b) lower lung field, and c) histolog
septal thickening, diffuse micronodular shadows, and bilateral pleural effusion
are shown (c).infiltration with no evidence of mycobacteria (Figure 1c).
A typical epithelioid noncaseating granuloma was not
found in the tissue. Although a case of acute eosinophilic
pneumonia associated with intravesical BCG therapy was
reported previously [9], clear eosinophil infiltration was
also not observed. An examination of the pleural effu-
sion revealed lymphocytic pleurisy; 68% lymphocytes, 17%
neutrophils, 14% macrophages, and 1% eosinophils. Ad-
enosine deaminase (ADA) in the pleural effusion was 18.8
U/l (5.0-20.0). Pleural needle biopsy was not performed
due to the insufficient buildup of effusion. The peripheral
blood lymphocyte stimulation test (LST) of BCG was
strongly positive (stimulation index 345%).
Immunotherapy with BCG was discontinued because
complications appeared to be due to a hypersensitivity
reaction to BCG, and methylprednisolone pulse therapy
(500 mg × 3 days) was started followed by a reduction in
the dose of prednisolone to 25 mg daily. Clinical symp-
toms, hypoxemia, and abnormal findings on chest X-ray
improved after 1 month of this treatment. Prednisolone
was tapered to complete withdrawal in a 2-month period.
Discussion
In this case, pulmonary complications arose despite
prophylactic treatment with a combination of isoniazid
and rifampicin, and no acid-fast bacillus could be identi-
fied in recovered BALF or pleural effusion. Moreover,
transbronchial lung biopsy revealed lymphocytic inflam-
mation without the detection of mycobacterium. The pa-
tient reacted well to steroid therapy, which also confirmed
that a disseminated BCG infection was unlikely.
In contrast to the decreased CD4+/CD8+ ratio re-
ported in typical HP patients, marked T helper cell alve-
olitis was found by BAL, as reported in previous cases
[2]. Since CD4+ alveolar lymphocytosis in the healthyy of transbronchial lung biopy. Ground-glass opacity, interlobular
are visible (a, b). Alveolar septal thickening and lymphocyte infiltration
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was reported previously [10], an increased CD4+/CD8+
ratio in BAL may imply intense immunosensitivity to-
ward BCG antigens. Although IFN-γ, IL-12, and TNF-α,
which were shown to be involved in the pathogenesis of
HP in animal models and in vitro experiments [11,12],
did not reach detectable values in the BALF of our pa-
tient, the high level of IL-8, which is a chemoattractant
for T lymphocytes and neutrophils, was consistent with
that in patients with HP [8].
LST is an examination that examines the sensitivity of
a suspected material by measuring the proliferation of T
cells to the material in vitro, from which one can con-
clude a previous in vivo reaction due to sensitization
[13]. Since the LST of BCG was positive in our case, the
hematogenous spread of the proteic component of BCG
during a traumatic third endoscopic treatment has fa-
vored a hypersensitive reaction in a previously sensitized
patient.
Patients with pulmonary tuberculosis or tuberculous
pleurisy have significantly higher levels of serum KL-6
than those of healthy controls. However, the mean
values of these tubercular illnesses were reported to be
less than 500 U/ml [14]. In contrast, circulating KL-6
levels were shown to be markedly increased in particular
types of drug-induced lung injury such as diffuse alveo-
lar damage and chronic interstitial pneumonia patterns
[15], and an elevated serum KL-6 level is one character-
istic of active HP (1,508 ± 647 U/ml [5]). In addition,
Kohno et al. reported that a high level of KL-6 in the
BALF was observed in 100% (8 of 8) of patients with HP
[6]. Another study indicated that serum KL-6 levels did
not increase in drug-induced pneumonitis with a HP
pattern (diffuse ground-glass opacities without fibrosis)
[15]. Although KL-6 levels in patients with interstitial
pneumonia secondary to intravesical BCG immunother-
apy have not been evaluated previously, serum and
BALF KL-6 levels in our patient were within normal
ranges. The difference observed in KL-6 levels suggests
that pulmonary epithelial cell injury caused by BCG-
induced pneumonitis may not be as prominent as that
of the common type of HP.
Caramori et al. recently reviewed the community-
acquired pulmonary complications of intravesical BCG
immunotherapy in 15 patients, including their own pa-
tient. Chest imaging of these cases revealed a military
pattern (n = 12), bilateral pulmonary opacities (n = 2),
and reticulonodular pattern (n = 1). However, the pleural
effusion was not included [16]. Although BCG-induced
parenchymal infiltration with a modest homolateral
pleural reaction was observed in a patient with COPD
and a history of previous tuberculosis in one case report,
the presence of pleural effusion and details of the
“pleural reaction” were not described [17].The main disease that shows lymphocytic pleural effu-
sion is tuberculous pleurisy. The pathogenesis of primary
tuberculous pleurisy is a hypersensitivity immunogenic
reaction to a few mycobacterial antigens entering the
pleural space rather than direct tissue destruction by un-
controlled mycobacterial proliferation [18]. An injection
of BCG into the pleural space of animals previously sen-
sitized by intradermal BCG can induce experimental tu-
berculous pleurisy [19]. These findings suggest that the
hypersensitivity reaction to BCG antigens may be the
mechanism of lymphocytic pleurisy in our patient.
The number of macrophages was larger in the pleural
effusion than in the BALF in this case. Although the role
of macrophages in tuberculous pleurisy remains unclear,
stimulated human pleural mesothelial cells were shown
to produce monocyte chemotactic protein-1 (MCP-1),
which is known to be elevated in tuberculous pleural
fluid [20,21]. Interactions between macrophages and
lymphocytes may have been present in the pleural space
of our patient.
We could not analyze the antigen-antibody reaction in
our patient. However, the presence of serum-specific
IgG to BCG was reported previously in a patient with
BCG-induced pneumonitis [22]. In addition, the level of
ADA, which is related to the proliferation of T lympho-
cytes, in the pleural effusion of our patient was not
higher than that in patients with typical tuberculous
pleurisy. These findings suggest that the hypersensitivity
reaction was induced not only by cell-mediated immun-
ity, but also by humoral immunity in patients treated
with BCG.Conclusion
This is the first case report of interstitial pneumonia
with lymphocytic pleurisy following BCG immunother-
apy. We suggest that the pathogenesis of our case may
have been a hypersensitive reaction to the proteic com-
ponent of BCG entering the lung and pleural space,
which is different from the etiology of the common type
of HP.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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